Rare Medical News
Spotlight On
Alopecia totalis (AT)
Alopecia totalis is the loss of all skull and facial hair
Prevalence
30 / 100,000
Age of Onset
ICD-10
#N/A
Inheritance
Autosomal dominant
Autosomal recessive
Mitochondrial/Multigenic
X-linked dominant
X-linked recessive
5 Facts you should know
FACT
A condition characterized by the complete loss of hair on the scalp
FACT
An advanced form of alopecia areata
FACT
It is thought to be an autoimmune condition in which the immune system mistakenly attacks the hair follicles
FACT
Roughly 20% of affected people have a family member with alopecia
FACT
Among those in whom all body hair is lost, fewer than 10% recover
Interest over time
Google searches
Common signs & symptoms
Alopecia of scalp
Current treatments
Everolimus(Brand name: Afinitor)
Manufactured by Novartis Pharmaceuticals Corporation
FDA-approved indication: April 2018 approved for the adjunctive treatment of adult and pediatric patients age 2 years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures. April 2012 approved for the treatment of adults with renal angiomyolipoma and tuberous sclerosis complex (TSC) not requiring immediate surgery. October 2010 approved for the treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis who require therapeutic intervention but are not candidates for curative surgical resection.
National Library of Medicine Drug Information Portal
Medline Plus Health Information
Vigabatrin(Brand name: Sabril)
Manufactured by Lundbeck
FDA-approved indication: For infantile spasms (IS) 1 month to 2 years of age
National Library of Medicine Drug Information Portal
Medline Plus Health Information
Top Clinical Trials
| Title | Description | Phases | Status | Interventions | More Information |
|---|---|---|---|---|---|
| PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA | This is a global Phase 2a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of ritlecitinib in adults aged 18 to ≤50 years of age with ≥25% scalp hair loss due to Alopecia Areata (AA). | Phase 2 | Active, not recruiting | Drug: PF-06651600|Drug: Placebo | Click here for more information |
| Long-Term PF-06651600 for the Treatment of Alopecia Areata | This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (PF-06651600) in adults and adolescents (12 years and older) who have alopecia areata. | Phase 3 | Active, not recruiting | Drug: PF-06651600|Biological: Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine|Biological: Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine | Click here for more information |
Top Treatments in Research
| Agent | Class/Mechanism of Action | Development Status | Company | Clinical Studies | More Information |
|---|---|---|---|---|---|
| PF-06651600 | An irreversible inhibitor of JAK3 with selectivity over the other three JAK isoforms. | Phase 2 | Pfizer | Click here for more information | Click here for more information |